papillary thyroid carcinoma
Conditions
Interventions
Experimental group:Nanosecond pulse tumor ablation
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old <= age <= 70 years old, gender is not limited; 2. Preoperative fine-needle aspiration biopsy cytological examination or coarse-needle aspiration biopsy histopathological examination suggested patients with primary papillary thyroid carcinoma; 3. Patients with non-high-risk subtypes; 4. Patients with a single tumor with a maximum diameter of <= 10 mm; 5. Patients with complete thyroid capsule and no obvious signs of invasion; 6. Patients with no suspicious metastatic lymph nodes or distant metastases visible in imaging; 7. Patients who refuse surgery or clinical observation, agree to participate in this clinical trial and voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of thyroid surgery or radioactive iodine therapy; 2. Patients with a history of epilepsy or recent myocardial infarction; 3. Patients with large calcifications in thyroid microcarcinoma; 4. Patients with contralateral vocal cord dysfunction; 5. Patients with cardiac pacemakers or implants such as metal stents in their bodies; 6. Patients with severe coagulation dysfunction or significant bleeding tendency (platelets 1.5 times the upper limit of normal value); 7. Severe failure of major organs (liver, kidney, heart, lung, brain, etc.) Patients with a survival period of less than 1 year; 8. Those who are known to be allergic to contrast media; 9. Patients with disturbance of consciousness or unable to cooperate with treatment; 10. Pregnant and lactating women; 11. Patients who are participating in other drug or device trials; 12. Patients considered by other researchers to be unsuitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete disappearance rate of target lesions within 365 days after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete ablation rate immediately after operation;Volume reduction rate of target lesions at 90, 180 and 365 days after operation;Complete disappearance rate of target lesions within 180 days after operation;Tumor recurrence rate within 365 days after operation;Incidence of cervical lymph node metastasis within 365 days after operation; | — |
Countries
China
Contacts
Public ContactGang Dong
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed